Form 4: Cytek Biosciences Director Jack Ball Receives Significant Equity Awards

Cytek Biosciences, Inc. Director Jack Ball was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, aligning his interests with shareholders.

Summary

• Jack Ball, a Director of Cytek Biosciences, Inc. (CTKB), reported the acquisition of equity awards on June 18, 2025.
• The awards include 43,973 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• The RSU Award vests 100% on the earlier of June 18, 2026, and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).
• Additionally, Mr. Ball received options to purchase 23,809 shares of common stock, with an exercise price of $3.07 per share.
• The stock options also vest 100% on the earlier of June 18, 2026, and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).
• The stock options have an expiration date of June 18, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Form 4 is primarily a disclosure of insider transactions and not a direct indicator of company performance, the granting of equity awards to a director is a positive sign as it aligns management's interests with shareholders and is a standard practice for incentivizing leadership.

Positives

• The granting of equity awards to a director, Jack Ball, aligns his financial interests directly with the long-term performance and shareholder value of Cytek Biosciences, Inc.
• The awards serve as a form of compensation that incentivizes the director to contribute to the company's growth and success.

Future Outlook

The future outlook indicates that the awarded Restricted Stock Units and stock options are set to vest on or before June 18, 2026, contingent on the company's 2026 annual meeting schedule, which will result in the director gaining full beneficial ownership of these shares.

Industry Context

The granting of equity awards such as Restricted Stock Units and stock options to directors is a common and standard practice across the life sciences and biotechnology industries. This compensation structure is widely used to attract and retain experienced board members and to align their incentives with the long-term interests of the company and its shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a component of director compensation is a standard practice in the biotechnology sector, comparable to compensation structures at companies like Illumina, Inc. (ILMN) or Bio-Rad Laboratories, Inc. (BIO).
• The vesting schedule, tied to a specific date or the next annual meeting, is typical for such awards, ensuring continued commitment from the director.
• The exercise price of $3.07 for the options, if it reflects the market price at the time of grant, is consistent with standard option grants designed to provide value based on future stock appreciation.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Restricted Stock Units and stock options are expected to vest on the earlier of June 18, 2026, or the date of Cytek Biosciences' 2026 annual meeting of stockholders (if held in June 2026).

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Director Compensation, Equity Award, Beneficial Ownership